RT Book, Section
A1 Talbert, Robert L.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1161376351
T1 Dyslipidemia
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1161376351
RD 2024/04/24
AB Content  UpdateFebruary  1,  2019New  Cholesterol  Management  Guidelines  Emphasize  Practicality  and  Clinical  Judgment:  The  2018  AHA/ACC  Guideline  on  the  Management  of  Blood  Cholesterol  reinforces  the  need  to  encourage  lifestyle  modification  to  prevent  atherosclerotic  cardiovascular  disease  (ASCVD)  and  to  use  high-potency  statins  in  patients  at  high  risk  of  major  adverse  cardiovascular  (CV)  events.  LDL-C  targets  have  been  re-introduced  into  the  guidelines.  Combination  therapy  using  a  statin  plus  either  ezetimibe  or  a  PCSK-9  inhibitor  should  be  considered  in  very  high-risk  patients  who  do  not  reach  their  LDL-C  target.  Clinicians  and  patients  can  now  consider  a  wider  array  of  risk-enhancing  factors  when  making  treatment  decisions.  Most  patients  no  longer  need  to  fast  before  obtaining  a  lipid  profile.